Charlie’s (OTCMKTS:CHUC – Get Rating) is one of 59 public companies in the “Medicinals & botanicals” industry, but how does it compare to its rivals? We will compare Charlie’s to similar businesses based on the strength of its dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
14.3% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 50.5% of Charlie’s shares are held by insiders. Comparatively, 22.3% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Charlie’s and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Charlie’s | -6.02% | -51.60% | -17.95% |
Charlie’s Competitors | -10.90% | -83.00% | 22.53% |
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Charlie’s | 0 | 0 | 0 | 0 | N/A |
Charlie’s Competitors | 212 | 564 | 812 | 43 | 2.42 |
As a group, “Medicinals & botanicals” companies have a potential upside of 97.74%. Given Charlie’s’ rivals higher possible upside, analysts clearly believe Charlie’s has less favorable growth aspects than its rivals.
Volatility and Risk
Charlie’s has a beta of 4.62, meaning that its share price is 362% more volatile than the S&P 500. Comparatively, Charlie’s’ rivals have a beta of 1.16, meaning that their average share price is 16% more volatile than the S&P 500.
Valuation & Earnings
This table compares Charlie’s and its rivals top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Charlie’s | $26.42 million | -$1.59 million | -9.80 |
Charlie’s Competitors | $282.79 million | -$103.81 million | -5.39 |
Charlie’s’ rivals have higher revenue, but lower earnings than Charlie’s. Charlie’s is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
About Charlie’s
Charlies Holdings, Inc. offers nicotine-only, e-cigarette and hemp-derived, CBD wellness liquid spaces through its subsidiary companies, Charlie’s Chalk Dust LLC and Don Polly LLC. It offers its products under the Pachamama and Charlie’s Chalk Dust brands. The company was founded by Brandon Stump and Ryan Stump in January 2001 and is headquartered in Costa Mesa, CA.
Receive News & Ratings for Charlie's Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charlie's and related companies with MarketBeat.com's FREE daily email newsletter.